With the use of mRNA-loaded pBAEs, the prerequisites for a future application in vivo are given. Therefore, the application of pBAE NPs encapsulating CD80 mRNA to specifically transfect tumor cells presents a new promising strategy for the in vivo treatment of various cancers.

4 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD80 (CD80 Molecule)

Phase Ib of L-NMMA and Pembrolizumab (clinicaltrials.gov)

P1, N=12, Completed, The Methodist Hospital Research Institute | Active, not recruiting --> Completed

7 days ago

Trial completion • Mismatch repair • Tumor mutational burden • IO biomarker • MSI-H • dMMR

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)

PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation

Keytruda (pembrolizumab) • tilarginine (L-NMMA)

CARTA: Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma (clinicaltrials.gov)

P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

9 days ago

Trial completion date • Trial primary completion date

Bavencio (avelumab)

14d

Follicular adenoma of the thyroid with hyalinizing trabecular tumor-like pattern. (PubMed, Virchows Arch)

Distinguishing FA with HTT-like morphology from genuine HTT might have therapeutic and prognostic (follow-up) implications, based on the benign nature of the former and the low-risk biology of the latter. However, the full biological spectrum of this FA subtype and its genetic background need more delineation in larger future studies with long follow-up.

14 days ago

Journal

NKX2-1 (NK2 Homeobox 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)

15d

Undifferentiated Round Cell Sarcomas: A Comprehensive Review and Practical Diagnostic Guide with an Emphasis on Superficial Body Sites. (PubMed, Int J Surg Pathol)

We highlight an integrated diagnostic framework that combines morphology, broad immunohistochemical panels, and molecular testing. Accurate recognition of these tumors is essential, as correct classification directly informs prognosis and therapeutic decision-making.

15 days ago

Review • Journal

BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)

15d

Superficial CIC::DUX4 Sarcoma With Focal WT1 Expression: Histomorphologic Clues and Immunohistochemical Pitfalls. (PubMed, J Cutan Pathol)

We herein report a case of challenging CDS diagnosed by genomic profiling, with weak, focal cytoplasmic WT-1 positivity, positive staining for CD56, CD138 (subset), and CD4 (subset). This case highlights the challenges involved in evaluating cutaneous small round blue cell tumors based on morphology and immunohistochemistry alone, especially in the presence of an atypical immunophenotype.

15 days ago

Journal

WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • DUX4 (Double Homeobox 4) • ETV4 (ETS Variant Transcription Factor 4)

20d

GoTHAM: Targeted Therapy and Avelumab in Merkel Cell Carcinoma (clinicaltrials.gov)

P1/2, N=19, Active, not recruiting, Melanoma and Skin Cancer Trials Limited | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2027 --> Dec 2026

20 days ago

Enrollment closed • Trial completion date • Trial primary completion date

Bavencio (avelumab) • Lutathera (lutetium Lu 177 dotatate)

22d

EX-BOOST: Exercise to Boost Response to Checkpoint Blockade Immunotherapy (clinicaltrials.gov)

P=N/A, N=12, Active, not recruiting, AdventHealth Translational Research Institute | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Aug 2025

22 days ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 (clinicaltrials.gov)

P1/2, N=31, Not yet recruiting, University of Wisconsin, Madison

1 month ago

New P1/2 trial

Inqovi (decitabine/cedazuridine) • Zynyz (retifanlimab-dlwr)

Hsa-microRNA-34a-5p inhibits virus-negative Merkel cell carcinoma cell proliferation and migration by regulating cell cycle- and EMT-related pathways and suppresses tumor spheroid formation. (PubMed, J Dermatol Sci)

We provide the first functional evidence of the pleiotropic tumor suppressor role of hsa-miR-34a-5p in VN-MCC.

1 month ago

Journal

NOTCH1 (Notch 1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • MIR34A (MicroRNA 34a-5p) • CCNE2 (Cyclin E2) • JAG1 (Jagged Canonical Notch Ligand 1)

PNeoVCA: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=132, Recruiting, Mayo Clinic | N=36 --> 132 | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2025 --> Mar 2028

1 month ago

Enrollment change • Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

HER-2 negative

Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine